Research map: Bruton tyrosine kinase inhibitors and cardiovascular adverse events

Back to the article

Papers in this map

  1. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS) · Alexander Richard Lyon · 2022 · 3064 citations · Cited by this paper
  2. Activation of sigma non‐opioid intracellular receptor 1 (S1R) receptor inhibits plexin domain containing 2 (Plxdc2) driven microglial inflammation to ameliorate depressive‐like behaviours in mice · 2026 · Related
  3. 2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS) · Isabelle C. Van Gelder · 2024 · 2934 citations · Cited by this paper
  4. Acute anaphylactic and multiorgan inflammatory effects of Comirnaty in pigs: evidence of spike protein mRNA transfection and paralleling inflammatory cytokine upregulation · 2026 · Related
  5. 2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation · Jan Steffel · 2021 · 1127 citations · Cited by this paper
  6. A novel quinoline and manganese‐based carbon monoxide‐releasing molecule for intravesical therapy of bladder cancer · 2026 · Related
  7. Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia · Jennifer R. Brown · 2022 · 492 citations · Cited by this paper
  8. Novel BTK inhibitors and degraders for relapsed/refractory CLL/SLL: latest updates from ASH 2025 annual meeting · 2026 · Related
  9. The role of the NLRP3 inflammasome and pyroptosis in cardiovascular diseases · Stefano A Toldo · 2023 · 408 citations · Cited by this paper
  10. Serotonin engages divergent 5‐HT receptor pathways for cell type‐resolved modulation of prefrontal layer 5 microcircuits · 2026 · Related
  11. Incidence of Atrial Fibrillation and Relationship With Cardiovascular Events, Heart Failure, and Mortality · Rob A. Vermond · 2015 · 298 citations · Cited by this paper
  12. Decoding functional specialization in G protein‐coupled receptors (GPCRs) through evolution‐guided residue profiling · 2026 · Related
  13. Cardiovascular Toxicities Associated With Ibrutinib · Joe‐Elie Salem · 2019 · 266 citations · Cited by this paper
  14. Arrhythmias associated with immune checkpoint inhibitor therapy—A clinical perspective · 2026 · Related
  15. Ibrutinib-Mediated Atrial Fibrillation Attributable to Inhibition of C-Terminal Src Kinase · Ling Xiao · 2020 · 246 citations · Cited by this paper
  16. Pirtobrutinib after a Covalent BTK Inhibitor in Chronic Lymphocytic Leukemia · Anthony R. Mato · 2023 · 233 citations · Cited by this paper
  17. Incidence of Sudden Cardiac Death in the European Union · Jean‐Philippe Empana · 2022 · 201 citations · Cited by this paper
  18. Cancer Therapy–Related Hypertension: A Scientific Statement From the American Heart Association · Jordana B. Cohen · 2023 · 164 citations · Cited by this paper
  19. Ibrutinib increases the risk of hypertension and atrial fibrillation: Systematic review and meta-analysis · Daniel Caldeira · 2019 · 159 citations · Cited by this paper
  20. Cardiovascular Toxicities of BTK Inhibitors in Chronic Lymphocytic Leukemia · Cooper Quartermaine · 2023 · 128 citations · Cited by this paper
  21. Targeting B-Cell Receptor Signaling for Anticancer Therapy: The Bruton's Tyrosine Kinase Inhibitor Ibrutinib Induces Impressive Responses in B-Cell Malignancies · Adrian U. Wiestner · 2012 · 126 citations · Cited by this paper
  22. Detection of new atrial fibrillation in patients with cardiac implanted electronic devices and factors associated with transition to higher device-detected atrial fibrillation burden · Giuseppe Boriani · 2017 · 120 citations · Cited by this paper
  23. BTK inhibitors in CLL: second-generation drugs and beyond · Constantine Si Lun Tam · 2024 · 102 citations · Cited by this paper
  24. Zanubrutinib in patients with previously treated B-cell malignancies intolerant of previous Bruton tyrosine kinase inhibitors in the USA: a phase 2, open-label, single-arm study · Mazyar S. Shadman · 2022 · 95 citations · Cited by this paper
  25. Pirtobrutinib preclinical characterization: a highly selective, non-covalent (reversible) BTK inhibitor · Eliana B Gómez · 2023 · 95 citations · Cited by this paper
  26. Human Cytotoxic T Lymphocytes Form Dysfunctional Immune Synapses with B Cells Characterized by Non-Polarized Lytic Granule Release · Anna Kabanova · 2016 · 40 citations · Cited by this paper
  27. Ibrutinib, an Approved Tyrosine Kinase Inhibitor as a Potential Cause of Recurrent Polymorphic Ventricular Tachycardia · János Tomcsányi · 2016 · 36 citations · Cited by this paper
  28. Cardiovascular Magnetic Resonance Imaging in Patients With Ibrutinib-Associated Cardiotoxicity · Benjamin Harding Buck · 2023 · 33 citations · Cited by this paper
  29. TH2/TH1 Shift Under Ibrutinib Treatment in Chronic Lymphocytic Leukemia · Maria Cristina Puzzolo · 2021 · 31 citations · Cited by this paper
  30. Diagnosis and Management of Cardiovascular Adverse Effects of Targeted Oncology Therapies: Bruton’s Tyrosine Kinase, Immune Checkpoint, and Vascular Endothelial Growth Factor Inhibitors: 2025 ACC Concise Clinical Guidance · Sarju Ganatra · 2025 · 27 citations · Cited by this paper
  31. Ibrutinib and Bruton’s Tyrosine Kinase Inhibitors in Chronic Lymphocytic Leukemia: Focus on Atrial Fibrillation and Ventricular Tachyarrhythmias/Sudden Cardiac Death · Giuseppe Boriani · 2022 · 26 citations · Cited by this paper
  32. Identification and Characterization of ACP-5862, the Major Circulating Active Metabolite of Acalabrutinib: Both Are Potent and Selective Covalent Bruton Tyrosine Kinase Inhibitors · Terry Podoll · 2022 · 23 citations · Cited by this paper
  33. Ibrutinib induces rapid down‐regulation of inflammatory markers and altered transcription of chronic lymphocytic leukaemia‐related genes in blood and lymph nodes · Marzia Palma · 2018 · 21 citations · Cited by this paper
  34. Small-molecule-induced ERBB4 activation to treat heart failure · Julie M. T. Cools · 2025 · 21 citations · Cited by this paper
  35. A Perfect Storm: Tyrosine Kinase Inhibitor-Associated Polymorphic Ventricular Tachycardia · Alexander B. Beyer · 2016 · 20 citations · Cited by this paper
  36. Cardiovascular toxicity of Bruton tyrosine kinase inhibitors: forget about selectivity but watch the clock · Giorgio Minotti · 2024 · 16 citations · Cited by this paper
  37. Pirtobrutinib monotherapy in Bruton tyrosine kinase inhibitor-intolerant patients with B-cell malignancies: results of the phase I/II BRUIN trial · Nirav Niranjan Shah · 2024 · 15 citations · Cited by this paper
  38. EHA Guidelines on management of chronic lymphocytic leukemia and Richter transformation · Barbara F. Eichhorst · 2026 · 11 citations · Cited by this paper
  39. Effectiveness and Safety of Apixaban Versus Warfarin in Atrial Fibrillation Patients With Malignancy: A Propensity-Matched Analysis · Siddharth pravin Agrawal · 2026 · 11 citations · Cited by this paper

Source: OpenAlex (CC0)